{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:00:59Z","timestamp":1782367259117,"version":"3.54.5"},"reference-count":87,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clml.2021.06.008","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T06:50:12Z","timestamp":1624431012000},"page":"641-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["SOHO State of the Art Updates and Next Questions: Identifying and Treating \u201cProgression\u201d in Myelofibrosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Prithviraj","family":"Bose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.06.008_bib0001","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0002","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kroger","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.008_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.06.008_bib0004","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0005","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2015-03-635235","article-title":"The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis","volume":"126","author":"Deininger","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0006","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.06.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.008_bib0008","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"COMFORT-I investigators. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clml.2021.06.008_bib0011","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0012","first-page":"1243","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"26","author":"Palandri","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.06.008_bib0013","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0014","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0015","first-page":"1","article-title":"Management of myelofibrosis after ruxolitinib failure","author":"Bose","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.06.008_bib0016","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2018-02-785923","article-title":"How I treat myelofibrosis after failure of JAK inhibitors","volume":"132","author":"Pardanani","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0018","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.06.008_bib0019","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0021","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2019-129288","article-title":"Fedratinib induces spleen responses and reduces symptom burden in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) and low platelet counts, who were either ruxolitinib-na\u00efve or were previously treated with ruxolitinib","volume":"136","author":"Harrison","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0022","first-page":"4197","article-title":"Case series of potential Wernicke's encephalopathy in patients treated with fedratinib","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0023","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/leu.2017.330","article-title":"Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis","volume":"32","author":"Pardanani","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.008_bib0024","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.2016.148924","article-title":"A phase 1\/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis","volume":"102","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.008_bib0025","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood-2016-09-740092","article-title":"Momelotinib inhibits ACVR1\/ALK2, decreases hepcidin production and ameliorates anemia of chronic disease in rodents","volume":"129","author":"Asshoff","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0026","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.06.008_bib0027","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ajh.23406","article-title":"Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in janus kinase inhibitor-naive patients with myelofibrosis","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0029","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0030","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0031","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.06.008_bib0032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.clml.2021.06.008_bib0033","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2(V617F) inhibitor, in patients with myelofibrosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0034","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0035","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0036","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.06.008_bib0037","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.06.008_bib0038","doi-asserted-by":"crossref","first-page":"33416","DOI":"10.18632\/oncotarget.26058","article-title":"Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy","volume":"9","author":"Singer","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2021.06.008_bib0039","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","article-title":"The myelodepletive phenotype in myelofibrosis: clinical relevance and therapeutic implication","volume":"20","author":"Marcellino","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.06.008_bib0040","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0041","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.008_bib0042","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.008_bib0043","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.06.008_bib0044","first-page":"53","article-title":"Favorable overall survival with imetelstat treatment correlates with other clinical benefits in intermediate 2 or high risk myelofibrosis relapsed\/refractory to janus kinase inhibitor","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.06.008_bib0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2020-138818","article-title":"Potential disease-modifying activity of imetelstat demonstrated by reduction in cytogenetically abnormal clones and mutation burden leads to clinical benefits in relapsed\/refractory myelofibrosis patients","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0046","first-page":"3084","article-title":"Imetelstat treatment results in clinical benefits, including improved overall survival, in patients with higher-risk triple-negative myelofibrosis relapsed\/refractory to janus kinase inhibitors (JAKi)","volume":"136","author":"Kiladjian","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.06.008_bib0047","first-page":"347","article-title":"Telomerase activity, telomere length and hTERT expression correlate with clinical outcomes in higher-risk myelofibrosis (MF) relapsed\/refractory (R\/R) to janus kinase inhibitor treated with imetelstat","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood."},{"issue":"29","key":"10.1016\/j.clml.2021.06.008_bib0048","first-page":"43","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2021.06.008_bib0049","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-140901","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-inhibitor-na\u00efve myelofibrosis patients: update of MANIFEST phase 2 study","volume":"136","author":"Mascarenhas","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0050","first-page":"2163","article-title":"CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory\/intolerant to JAK inhibitor: update from phase 2 MANIFEST study","volume":"136","author":"Talpaz","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0051","first-page":"56","article-title":"CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as \u201cadd-on\u201d to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: update of MANIFEST phase 2 study","volume":"136","author":"Verstovsek","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0052","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","article-title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","volume":"57","author":"Al-Ali","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.06.008_bib0053","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.3324\/haematol.2016.151449","article-title":"The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies","volume":"101","author":"Gupta","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.008_bib0054","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2018-11-876888","article-title":"Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis","volume":"133","author":"Fenaux","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0055","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.06.008_bib0056","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia","volume":"134","author":"Guerra","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0057","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2019-122546","article-title":"A phase 2 study of luspatercept in patients with myelofibrosis-associated anemia","volume":"134","author":"Gerds","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0058","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood-2020-137265","article-title":"Duration of response to luspatercept in patients (Pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF)-updated data from the phase 2 ACE-536-MF-001 study","volume":"136","author":"Gerds","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.06.008_bib0059","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/onc.2011.313","article-title":"JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms","volume":"31","author":"Nakatake","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2021.06.008_bib0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1172\/JCI39194","article-title":"TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer","volume":"120","author":"Araki","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2021.06.008_bib0061","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","article-title":"P53 lesions in leukemic transformation","volume":"364","author":"Harutyunyan","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.06.008_bib0062","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.06.008_bib0063","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.06.008_bib0064","first-page":"S215","article-title":"KRT-232, a first-in-class, murine double minute 2 inhibitor, for myelofibrosis relapsed or refractory to janus-associated kinase inhibitor treatment","volume":"4","author":"Al-Ali","year":"2020","journal-title":"Hemasphere."},{"key":"10.1016\/j.clml.2021.06.008_bib0065","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1182\/bloodadvances.2020002379","article-title":"Transient expansion of TP53 mutated clones in polycythemia vera patients treated with idasanutlin","volume":"4","author":"Marcellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.06.008_bib0066","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1358\/dnp.2010.23.5.1444206","article-title":"PRM-151 (recombinant human serum amyloid P\/pentraxin 2) for the treatment of fibrosis","volume":"23","author":"Duffield","year":"2010","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.clml.2021.06.008_bib0067","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","article-title":"Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial","volume":"319","author":"Raghu","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2021.06.008_bib0068","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0069","first-page":"S828","article-title":"A randomized, double blind phase 2 study of 3 different doses of PRM-151 in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib","author":"Verstovsek","year":"2019","journal-title":"Hemasphere."},{"key":"10.1016\/j.clml.2021.06.008_bib0070","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.celrep.2013.10.038","article-title":"Combined targeting of JAK2 and Bcl-2\/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors","volume":"5","author":"Waibel","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2021.06.008_bib0071","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2021.06.008_bib0072","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2020-136938","article-title":"The addition of navitoclax to ruxolitinib demonstrates efficacy within different high-risk populations in patients with relapsed\/refractory myelofibrosis","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0073","first-page":"S216","article-title":"Addition of parsaclisib, A PI3KDELTA inhibitor, in patients (PTS) with suboptimal response to ruxolitinib (RUX): a phase 2 study in PTS with myelofibrosis (MF)","volume":"4","author":"Yacoub","year":"2020","journal-title":"Haemasphere"},{"key":"10.1016\/j.clml.2021.06.008_bib0074","first-page":"51","article-title":"A phase 2 study of the LSD1 inhibitor IMG7289 (bomedemstat) for the treatment of advanced myelofibrosis","volume":"136","author":"Yacoub","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.008_bib0076","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/leu.2016.215","article-title":"A Phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis","volume":"31","author":"Verstovsek","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.008_bib0077","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V128.22.1936.1936","article-title":"Phase 1\/2 study of NS-018, an oral JAK2 inhibitor, in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (postPV MF), or post-essential thrombocythemia myelofibrosis (postET MF)","volume":"128","author":"Verstovsek","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.clml.2021.06.008_bib0078","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2019-130046","article-title":"Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic\/IAP antagonist for patients with intermediate to high risk myelofibrosis","volume":"136","author":"Pemmaraju","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0079","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.06.008_bib0080","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/blood-2020-137572","article-title":"A multicenter phase 1\/2 clinical trial of tagraxofusp, a CD123-targeted therapy, in patients with poor-risk primary and secondary myelofibrosis","volume":"136","author":"Pemmaraju","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0081","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2020-137294","article-title":"Results of a phase II study of PD-1 inhibition in advanced myeloproliferative neoplasms","volume":"136","author":"Hobbs","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0082","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/bjh.14501","article-title":"A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis","volume":"176","author":"Verstovsek","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.06.008_bib0083","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/10428194.2013.805329","article-title":"Anti-transforming growth factor-beta therapy in patients with myelofibrosis","volume":"55","author":"Mascarenhas","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.06.008_bib0084","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2017.177600","article-title":"Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with MPNs","volume":"103","author":"Hobbs","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.008_bib0085","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2019-127661","article-title":"Safety and efficacy of combined ruxolitinib and thalidomide in patients with myelofibrosis: a phase II study","volume":"134","author":"Rampal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.008_bib0086","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"Sorensen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.008_bib0087","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","article-title":"Ruxopeg, a multi-center bayesian phase 1\/2 adaptive randomized trial of the combination of ruxolitinib and pegylated interferon alpha 2a in patients with myeloproliferative neoplasm (MPN)-associated myelofibrosis","volume":"132","author":"Kiladjian","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100238X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502100238X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:54Z","timestamp":1761871014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502100238X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":87,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S215226502100238X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: Identifying and Treating \u201cProgression\u201d in Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}